Y Intercept Hong Kong Ltd Makes New Investment in BioAge Labs, Inc. $BIOA

Y Intercept Hong Kong Ltd acquired a new position in BioAge Labs, Inc. (NASDAQ:BIOA) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 201,337 shares of the company’s stock, valued at approximately $3,521,000. Y Intercept Hong Kong Ltd owned about 0.45% of BioAge Labs as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the company. CWM LLC lifted its stake in shares of BioAge Labs by 39.9% in the fourth quarter. CWM LLC now owns 3,693 shares of the company’s stock valued at $49,000 after buying an additional 1,053 shares in the last quarter. Russell Investments Group Ltd. bought a new stake in shares of BioAge Labs in the third quarter valued at approximately $27,000. China Universal Asset Management Co. Ltd. purchased a new position in BioAge Labs in the 4th quarter valued at approximately $77,000. Nisa Investment Advisors LLC raised its holdings in BioAge Labs by 4,219.4% during the 4th quarter. Nisa Investment Advisors LLC now owns 10,237 shares of the company’s stock valued at $135,000 after acquiring an additional 10,000 shares during the period. Finally, Bank of America Corp DE grew its position in shares of BioAge Labs by 46.3% in the third quarter. Bank of America Corp DE now owns 11,119 shares of the company’s stock valued at $65,000 after purchasing an additional 3,517 shares in the last quarter.

BioAge Labs Stock Down 3.0%

BIOA traded down $0.74 during trading on Tuesday, hitting $24.10. The company’s stock had a trading volume of 110,401 shares, compared to its average volume of 612,557. BioAge Labs, Inc. has a one year low of $4.11 and a one year high of $25.95. The firm has a market cap of $1.07 billion, a PE ratio of -10.05 and a beta of 0.61. The business’s 50 day simple moving average is $18.84 and its 200-day simple moving average is $18.42.

BioAge Labs (NASDAQ:BIOA) last posted its quarterly earnings data on Friday, May 8th. The company reported ($0.52) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.71) by $0.19. The business had revenue of $2.77 million during the quarter. BioAge Labs had a negative return on equity of 29.40% and a negative net margin of 871.75%. Equities research analysts expect that BioAge Labs, Inc. will post -2.68 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on BIOA shares. Needham & Company LLC assumed coverage on shares of BioAge Labs in a report on Friday, March 27th. They issued a “buy” rating and a $50.00 price target on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BioAge Labs in a report on Friday, April 24th. Citigroup upped their target price on BioAge Labs from $15.00 to $52.00 and gave the stock a “buy” rating in a research note on Tuesday, March 10th. Wall Street Zen lowered shares of BioAge Labs from a “hold” rating to a “sell” rating in a report on Sunday, May 17th. Finally, BTIG Research initiated coverage on shares of BioAge Labs in a report on Wednesday, May 13th. They issued a “buy” rating and a $40.00 target price on the stock. Six investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $43.50.

BioAge Labs Company Profile

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.